FDA Approves J&J's Concerta for Treatment of ADHD in Adults
Posted on: Monday, 30 June 2008, 12:03 CDT
Johnson & Johnson Pharmaceutical Research & Development has received the FDA approval for the company's supplemental new drug application for Concerta treatment of ADHD in adults ages 18 to 65. The doses approved for adults range from 18 to 72mg daily.
The FDA approval was based on clinical trial data in adults ages 18 to 65. In these studies, use of Concerta was shown to significantly improve ADHD symptoms such as attention, impulsivity and hyperactivity compared to placebo, and the medication was shown to be generally well tolerated.
The approval expands the Concerta indication from children and adolescents into adults with ADHD, and offers these patients a patented once- daily formulation.
Using its unique OROS delivery system, the Concerta formulation delivers an initial dose of medication when the tablet is ingested. Medication is then delivered into the bloodstream at a controlled rate throughout the day.
Source: Datamonitor
Related Articles
- Chronic and Complex Diseases on the Rise in Philadelphia: Adults Using More Medications to Treat Chronic Conditions
- Shire Wins Approval for ADHD Drug in Adults
- Shire May Get FDA Approval for ADHD Drug
- FDA Approves Shire's ADHD Drug Vyvanse
- Noven Approved for ADHD Patch
- Janssen to Seek Approval for ADHD Drug in Japan
- Sanmina-SCI Selects NI Modular Instruments and PXI to Build FDA-Approved Medical Device Test System
- Md. Lawmakers OK Medical Malpractice Bill
- Justices Appear Unlikely to Approve Medical Use of Marijuana
 |
 |
User Comments (0)
RSS Feeds